Findings support next-generation sequencing-based ctDNA as a prognostic biomarker to refine risk stratification in patients undergoing neoadjuvant therapy.
Krishay Sridalla, Dominic J. Vitello, Madison Cox et al.· Annals of Surgical Oncology· 0 citations
Gliomas are the most prevalent and aggressive primary tumors of the central nervous system (CNS), with glioblastoma demonstrating particularly poor survival rates despite multimodal treatment approaches. The extensive molecular heterogeneity and resistance to conventional therapies highlight the urgent need for novel b...
J. Machhi, Priya U. Kumthekar, Stella Hartmann· Cancers· 0 citations
BACKGROUND
Pancreatic ductal adenocarcinoma (PDAC) carries high mortality despite neoadjuvant chemotherapy (NAC) and surgical resection, creating an urgent need for prognostic biomarkers to guide treatment. We aimed to determine whether circulating tumor DNA (ctDNA) detected by next-generation sequencing (NGS) predicts...
Krishay Sridalla, Dominic J. Vitello, Madison Cox et al.· Annals of Surgical Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.